WebPurpose: Pulmonary embolism (PE) can lead to significant morbidity and mortality. Thrombolytics are currently approved for the treatment of massive PE; however, the CHEST guidelines recommend against systemic thrombolytic use in acute PE patients without hypotension, unless these patients deteriorate on anticoagulation alone.

How to dose and monitor argatroban for treatment of HIT

WebFamiliarity with monitoring and dosing, the weight of evidence from studies in the medical intensive care patient population, and cost were factors favoring the recommendation of … WebObjective: Argatroban, a direct thrombin inhibitor, was evaluated for anticoagulation in continuous renal replacement therapy (CRRT) in critically ill patients with heparin … heather enterprises

Argatroban Injection, USP Dosage and Administration

WebBackground/aims: Argatroban, a hepatically metabolized direct thrombin inhibitor, is approved for use in heparin-induced thrombocytopenia (HIT; several countries) and in antithrombin-deficient patients undergoing hemodialysis (Japan). This literature analysis aimed to determine the effects of renal function on argatroban pharmacokinetics, … Web25 ott 2024 · Anticoagulation was maintained with argatroban and monitored based on activated clotting time (ACT) and aPTT, with target levels of 160–180 s and 50–70 s, respectively. Intraoperative argatroban doses ranged between 0.4 and 0.6 μg/kg/min, resulting in ACT of 162–207 s and aPTT of 45–75 s (Fig. 2). WebVenous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE). It is a common, lethal disease that is the third most common cause of hospital-related death and the most common preventable cause of hospital associated-death in the United States. movie braveheart 1995